Using the large genomic studies, TCGA and METABRIC, we were able to analyze the expression of NR4A1–NR4A3 in all BC subtypes, including Basal, Her2, Luminal A, and Luminal B. Basal BC is considered to be aggressive and metastatic, and effective therapeutic treatments are minimal (44). The gene discussed is NR4A3; the disease is breast cancer.